• {%brandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%subBrandMenuItems%}
    • {%itemName%} {%arrowSpan%}
        {%productMenuItems%}
    • {%selfProduct%}
      • {%languages%}
    • This website is for UK Healthcare Professionals only

      Expert Opinion

       

      Dr Raj Sengupta Unmet Needs in AS

      Clinical Summary Videos

       

      RINVOQ Discovery Journey & MOA

      SELECT AXIS 1

      Downloadable Clinical Summaries

      SELECT AXIS 1

      View a summary of the SELECT AXIS-1 clinical trial - Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial

      I want to find out more about RINVOQ

      I want to receive more information about RINVOQ

      UK-UPAD-220093. Date of preparation: March 2022

      Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
      Adverse events should also be reported to AbbVie on GBPV@abbvie.com